Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DILAUDID vs ALFENTANIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dilaudid (hydromorphone) is a full opioid agonist with high affinity for mu-opioid receptors, producing analgesia by mimicking endogenous endorphins and enkephalins. It also activates kappa and delta opioid receptors to a lesser extent.
Alfentanil is a potent, short-acting synthetic opioid analgesic that primarily acts as a mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system, leading to G-protein coupled activation of inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.
Management of moderate to severe pain in opioid-tolerant patients requiring an around-the-clock analgesic for an extended period,Off-label: acute pain management, preanesthetic medication, cough suppression
Analgesic adjunct during general anesthesia,Induction of anesthesia,Maintenance of anesthesia for short surgical procedures,Off-label: Procedural sedation in monitored settings
Initial: 2-4 mg orally every 4-6 hours as needed; or 1-2 mg intramuscularly, subcutaneously, or intravenously every 4-6 hours as needed.
Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-1.5 mcg/kg/min; incremental boluses of 5-10 mcg/kg as needed. Induction of anesthesia: 50-100 mcg/kg IV.
2.5-3.5 hours (terminal); prolonged in hepatic/renal impairment
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours). Clinically, context-sensitive half-time is short (~40 min after 3-hour infusion) due to rapid redistribution and metabolism.
Primarily hepatic via glucuronidation; major metabolites: hydromorphone-3-glucuronide (H3G, active) and hydromorphone-6-glucuronide (H6G); minor pathways: N-demethylation to norhydromorphone; CYP450 involvement minimal.
Alfentanil is primarily metabolized by hepatic cytochrome P450 enzymes, mainly CYP3A4, through oxidative N-dealkylation and O-demethylation to inactive metabolites.
Primarily renal (90% as hydromorphone-3-glucuronide and parent drug); <1% biliary/fecal
Primarily hepatic metabolism via CYP3A4; <1% excreted unchanged in urine; metabolites (mainly noralfentanil) excreted renally. Biliary/fecal excretion of metabolites accounts for ~30%.
~20% (primarily albumin)
~92% bound primarily to alpha-1-acid glycoprotein (AAG) and albumin.
1.2-1.7 L/kg; indicates extensive tissue distribution
Vd: 0.4–1.0 L/kg (mean ~0.75 L/kg). Moderate Vd reflecting rapid distribution to tissues, especially brain and muscle.
Oral: 50-60% (first-pass); IM: ~100%; Rectal: ~50-60%
IV: 100%. IM: ~90%. Epidural: ~30–50% due to local uptake and redistribution. No significant oral bioavailability.
e GFR 30-60 m L/min: Administer 75% of usual dose; e GFR <30 m L/min: Administer 50% of usual dose; avoid in severe impairment.
GFR 10-50 m L/min: administer with caution, consider dose reduction of 25-50%; GFR <10 m L/min: reduce dose by 50% and extend dosing interval.
Child-Pugh class A: No adjustment; Child-Pugh class B: Reduce dose by 25-50%; Child-Pugh class C: Avoid use or reduce dose by 50-75%.
Child-Pugh class A: no adjustment needed; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: reduce dose by 75%.
Children >12 years: 2-4 mg orally every 4-6 hours; 0.1-0.2 mg/kg intramuscularly/subcutaneously/intravenously every 4-6 hours (max single dose 4 mg).
Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-2 mcg/kg/min. For neonates, reduce dose by 30-50% due to immature clearance.
Initiate at 25-50% of adult dose; increase cautiously; monitor for respiratory depression, sedation, and constipation.
Reduce initial IV bolus by 30-50% to 3-10 mcg/kg; titrate carefully; monitor for prolonged sedation and respiratory depression.
Risk of respiratory depression, particularly in opioid-naive patients and those with respiratory compromise; risk of addiction, abuse, and misuse; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risk of fatal overdose when used with benzodiazepines or CNS depressants.
Risk of respiratory depression: Alfentanil can cause severe, life-threatening, or fatal respiratory depression. Monitor for respiratory depression, especially during initiation or following dose increases. Accidental ingestion of even one dose can be fatal. Concomitant use with central nervous system depressants (e.g., benzodiazepines, alcohol) may increase risk. Alfentanil is an opioid agonist and a Schedule II controlled substance with high potential for abuse and addiction.
Respiratory depression (especially with concurrent CNS depressants); addiction potential; risk of opioid-induced hyperalgesia; severe hypotension; adrenal insufficiency; androgen deficiency; impairment of mental/physical abilities; risk of serotonin syndrome with serotonergic drugs; risk of severe hypotension in hypovolemic patients; caution in elderly, cachectic, or debilitated patients.
Respiratory depression: Potentially fatal; monitor oxygenation and ventilation.,Abuse potential: Schedule II controlled substance; risk of addiction, abuse, and diversion.,Concomitant use with CNS depressants: Increases risk of profound sedation, respiratory depression, coma, and death; limit use or monitor closely.,Geriatric and cachectic patients: Increased sensitivity; reduce initial dose.,Hepatic impairment: Alfentanil clearance is reduced in patients with cirrhosis; consider dose adjustment.,Bradycardia and hypotension: Use with caution in patients with hypovolemia or reduced cardiac reserve.,Serotonin syndrome: Risk with concurrent serotonergic drugs (e.g., MAOIs, SSRIs, triptans); monitor for symptoms.,Withdrawal: Prolonged use may lead to physical dependence; taper dose gradually.
Significant respiratory depression; acute or severe bronchial asthma (in unmonitored settings); known or suspected gastrointestinal obstruction (e.g., paralytic ileus); hypersensitivity to hydromorphone or any excipients; concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days.
Hypersensitivity to alfentanil, fentanyl, or any opioid,Significant respiratory depression (e.g., acute asthma, COPD in acute exacerbation),Acute or severe bronchial asthma,Suspected or known paralytic ileus,MAO inhibitor use within 14 days (serotonin syndrome risk),Myasthenia gravis (relative contraindication due to risk of respiratory muscle weakness),Morbid obesity with sleep apnea (relative contraindication; increased risk of respiratory depression)
Avoid grapefruit juice as it may increase hydromorphone levels via CYP3A4 inhibition. High-fat meals may delay absorption of immediate-release formulations but do not significantly alter overall exposure. Maintain adequate fluid and fiber intake to prevent constipation.
No significant food interactions known. Avoid grapefruit and grapefruit juice as they may inhibit CYP3A4 metabolism, potentially prolonging effects.
First trimester: Limited human data; animal studies show no consistent teratogenicity. Second and third trimesters: Chronic use may cause fetal opioid dependence and neonatal abstinence syndrome (NAS). High doses near term may cause neonatal respiratory depression.
Alfentanil is an opioid analgesic; limited human data. No clear evidence of major malformations, but third trimester use may cause neonatal opioid withdrawal syndrome (NOWS). Avoid prolonged use or high doses near term; use during labor may cause respiratory depression in neonate.
Hydromorphone is excreted into breast milk in low concentrations. M/P ratio approximately 0.8-1.0 (estimated). Relative infant dose <2% of maternal weight-adjusted dose. Monitor infant for sedation, respiratory depression, and withdrawal. Use with caution, especially in preterm or compromised infants.
Alfentanil is excreted into breast milk in very low concentrations; estimated relative infant dose is low (<2% of maternal weight-adjusted dose). M/P ratio not determined in humans. Compatible with breastfeeding with caution; monitor infant for drowsiness, feeding difficulties.
Pregnancy increases clearance and volume of distribution for hydromorphone; dose may need to be increased or given more frequently, especially in the third trimester. Titrate to effect while avoiding excessive sedation. Postpartum, clearance returns to prepregnancy levels; reduce dose accordingly.
Pregnancy can alter alfentanil pharmacokinetics: increased volume of distribution, decreased plasma clearance, prolonged elimination half-life. Dose reduction may be needed for prolonged use; titrate to effect. During labor, use smallest effective dose.
Dilaudid (hydromorphone) is 5–10 times more potent than morphine. Use with caution in opioid-naive patients; start at low doses. Avoid in patients with significant respiratory depression, paralytic ileus, or acute asthma. Monitor for signs of hypotension, especially in hypovolemic patients. May cause histamine release with pruritus, but less than morphine. For breakthrough pain, immediate-release oral solution provides fastest oral onset. Not recommended for chronic pain without careful reassessment. Reversal with naloxone, but short infusion may be needed due to longer duration.
Alfentanil is a potent, short-acting synthetic opioid (4-5 times more potent than fentanyl) with rapid onset (1-2 min) and brief duration (5-10 min). Primarily used for induction and maintenance of anesthesia, especially in short procedures. Requires careful monitoring of respiratory depression and chest wall rigidity, particularly during rapid IV administration. Hepatic metabolism (CYP3A4) affected by liver disease; reduce dose. Decrease dose in elderly and hypovolemic patients. Not recommended for chronic pain due to short half-life.
Do not crush, chew, or break extended-release tablets; swallow whole.,Avoid alcohol and other CNS depressants (benzodiazepines, sedatives) as they increase risk of severe drowsiness, respiratory depression, coma, and death.,Do not drive or operate heavy machinery until you know how this medication affects you.,Store securely out of sight and reach of children; dispose of unused medication via take-back program or mixing with unpalatable substance and trashing.,Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Common side effects include drowsiness, dizziness, constipation, nausea, and vomiting. Laxatives and hydration may help constipation.,Seek emergency help if you have trouble breathing, slow heartbeat, severe dizziness, or fainting.,Tell all healthcare providers you are taking this medication before any surgery or procedure.,Do not stop suddenly without doctor guidance to avoid withdrawal symptoms (anxiety, sweating, diarrhea, muscle aches).
This medication causes drowsiness and dizziness; avoid driving or operating machinery for at least 24 hours after administration.,Report any difficulty breathing, chest tightness, or feeling faint immediately.,Alfentanil is used only in hospital settings under direct supervision of healthcare professionals.,Inform your doctor if you have a history of liver disease, lung disease, or drug/alcohol abuse.,Do not consume alcohol or other sedatives while under the effects of alfentanil.
No interactions on record
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DILAUDID vs ALFENTANIL, answered by our medical review team.
DILAUDID is a Opioid Analgesic that works by Dilaudid (hydromorphone) is a full opioid agonist with high affinity for mu-opioid receptors, producing analgesia by mimicking endogenous endorphins and enkephalins. It also activates kappa and delta opioid receptors to a lesser extent.. ALFENTANIL is a Opioid Analgesic that works by Alfentanil is a potent, short-acting synthetic opioid analgesic that primarily acts as a mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system, leading to G-protein coupled activation of inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DILAUDID and ALFENTANIL depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DILAUDID is: Initial: 2-4 mg orally every 4-6 hours as needed; or 1-2 mg intramuscularly, subcutaneously, or intravenously every 4-6 hours as needed.. The standard adult dose of ALFENTANIL is: Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-1.5 mcg/kg/min; incremental boluses of 5-10 mcg/kg as needed. Induction of anesthesia: 50-100 mcg/kg IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DILAUDID and ALFENTANIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DILAUDID is classified as Category C. First trimester: Limited human data; animal studies show no consistent teratogenicity. Second and third trimesters: Chronic use may cause fetal opioid dependence and neonatal absti. ALFENTANIL is classified as Category C. Alfentanil is an opioid analgesic; limited human data. No clear evidence of major malformations, but third trimester use may cause neonatal opioid withdrawal syndrome (NOWS). Avoid. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.